SNOA Relative Valuation
SNOA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, SNOA is overvalued; if below, it's undervalued.
Historical Valuation
Sonoma Pharmaceuticals Inc (SNOA) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -1.11. The fair price of Sonoma Pharmaceuticals Inc (SNOA) is between NaN to NaN according to relative valuation methord.
Relative Value
Fair Zone
NaN-NaN
Current Price：3.57
Fair
-3.84
PE
1Y
3Y
5Y
Trailing
Forward
0.00
EV/EBITDA
Sonoma Pharmaceuticals Inc. (SNOA) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is 0.40. The thresholds are as follows: Strongly Undervalued below -1.20, Undervalued between -1.20 and -0.40, Fairly Valued between 1.19 and -0.40, Overvalued between 1.19 and 1.99, and Strongly Overvalued above 1.99. The current Forward EV/EBITDA of 0.00 falls within the Historic Trend Line -Fairly Valued range.
-1.58
EV/EBIT
Sonoma Pharmaceuticals Inc. (SNOA) has a current EV/EBIT of -1.58. The 5-year average EV/EBIT is -1.05. The thresholds are as follows: Strongly Undervalued below -5.23, Undervalued between -5.23 and -3.14, Fairly Valued between 1.05 and -3.14, Overvalued between 1.05 and 3.14, and Strongly Overvalued above 3.14. The current Forward EV/EBIT of -1.58 falls within the Historic Trend Line -Fairly Valued range.
0.25
PS
Sonoma Pharmaceuticals Inc. (SNOA) has a current PS of 0.25. The 5-year average PS is 0.28. The thresholds are as follows: Strongly Undervalued below 0.04, Undervalued between 0.04 and 0.16, Fairly Valued between 0.40 and 0.16, Overvalued between 0.40 and 0.52, and Strongly Overvalued above 0.52. The current Forward PS of 0.25 falls within the Historic Trend Line -Fairly Valued range.
11.08
P/OCF
Sonoma Pharmaceuticals Inc. (SNOA) has a current P/OCF of 11.08. The 5-year average P/OCF is 1.14. The thresholds are as follows: Strongly Undervalued below -20.77, Undervalued between -20.77 and -9.81, Fairly Valued between 12.10 and -9.81, Overvalued between 12.10 and 23.05, and Strongly Overvalued above 23.05. The current Forward P/OCF of 11.08 falls within the Historic Trend Line -Fairly Valued range.
0.00
P/FCF
Sonoma Pharmaceuticals Inc. (SNOA) has a current P/FCF of 0.00. The 5-year average P/FCF is 0.70. The thresholds are as follows: Strongly Undervalued below -1.02, Undervalued between -1.02 and -0.16, Fairly Valued between 1.55 and -0.16, Overvalued between 1.55 and 2.41, and Strongly Overvalued above 2.41. The current Forward P/FCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.
Sonoma Pharmaceuticals Inc (SNOA) has a current Price-to-Book (P/B) ratio of 1.56. Compared to its 3-year average P/B ratio of 0.80 , the current P/B ratio is approximately 95.25% higher. Relative to its 5-year average P/B ratio of 1.13, the current P/B ratio is about 37.37% higher. Sonoma Pharmaceuticals Inc (SNOA) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -87.81%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -68.01% , the current FCF yield is about -100.00% lower.
1.56
P/B
Median3y
0.80
Median5y
1.13
-43.62
FCF Yield
Median3y
-87.81
Median5y
-68.01
Competitors Valuation Multiple
The average P/S ratio for SNOA's competitors is 0.00, providing a benchmark for relative valuation. Sonoma Pharmaceuticals Inc Corp (SNOA) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of 56.58%, this premium appears sustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of SNOA increased by 32.71% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 3.58M to 5.60M.
The secondary factor is the P/E Change, contributed 20.20%to the performance.
Overall, the performance of SNOA in the past 1 year is driven by Revenue Growth. Which is more sustainable.
People Also Watch
FAQ
Is Sonoma Pharmaceuticals Inc (SNOA) currently overvalued or undervalued?
What is Sonoma Pharmaceuticals Inc (SNOA) fair value?
How does SNOA's valuation metrics compare to the industry average?
What is the current P/B ratio for Sonoma Pharmaceuticals Inc (SNOA) as of Dec 05 2025?
What is the current FCF Yield for Sonoma Pharmaceuticals Inc (SNOA) as of Dec 05 2025?
What is the current Forward P/E ratio for Sonoma Pharmaceuticals Inc (SNOA) as of Dec 05 2025?